Asset Details
Do you wish to reserve the book?
CT changes in a randomized trial comparing early therapies in an outpatient population at high risk of severe COVID19 disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
CT changes in a randomized trial comparing early therapies in an outpatient population at high risk of severe COVID19 disease
Do you wish to request the book?
CT changes in a randomized trial comparing early therapies in an outpatient population at high risk of severe COVID19 disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
CT changes in a randomized trial comparing early therapies in an outpatient population at high risk of severe COVID19 disease
2025
Overview
Although in vitro studies suggest that neutralization by monoclonal antibodies (mAbs) against SARS CoV2 Omicron sub lineages is reduced, in vivo virological response data are lacking. MONET (EudraCT: 2021–004188-28) was multi-centric phase 4 open-label parallel randomized clinical trial, conducted in Italy over 2022–2023, to assess the efficacy of sotrovimab (SOT), tixagevimab/cilgavimab (TIX/CIL) and Nirmatrelvir/ritonavir (NMV/r), in outpatients at high risk for severe COVID-19. The outcome (secondary in the trial protocol) was SARS-CoV-2 variation in cycle threshold (CT) values over the first 7 days (D1-D7) of the trial. CT variation was compared by trial arms using unadjusted linear regression and after controlling for age. We included 346 individuals: 116 (34%) received SOT, 113 (33%) TIX/CIL, 117 (34%) NMV/r. Main characteristics were balanced across arms. Most of the participants were infected with BA.2 (52%) or BA.4/5 (35.5%). The data carried strong evidence that the mean CT change over D1-D7 was larger in subjects receiving NMV/r vs. the other arms (p < 0.001). We found no evidence that viral variant was an effect measure modifier for the contrasts of interest (p = 0.14). Our analysis provides strong evidence that NMV/r exerts a greater in vivo antiviral effect than anti-Spike mAbs against Omicron sub lineages, confirming previous in vitro data.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 692/308
/ 692/53
/ 692/700
/ Adult
/ Aged
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Antiviral Agents - therapeutic use
/ Chronic obstructive pulmonary disease
/ COVID-19
/ CT value
/ Female
/ Humanities and Social Sciences
/ Humans
/ Italy
/ Male
/ RCT
/ Science
